Knight Capital Group’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Knight Capital Group’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q2	$176K	Buy	+3,007	New	+$185K	﹤0.01%	2764

Other funds holding OREX

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Knight Capital Group's OREX Position: Q2 2013 in Review

Knight Capital Group opened a new position in Orexigen Therapeutics, Inc. (OREX) in Q2 2013: 3,007 shares worth $176K. The stake represents ﹤0.01% of the portfolio and ranks #2764 among its holdings.

123 funds tracked by Wall St. Rank hold OREX as of Q2 2013.

Knight Capital Group held 3,007 shares of Orexigen Therapeutics, Inc. worth $176K as of Q2 2013.
Orexigen Therapeutics, Inc. was a new Knight Capital Group position in Q2 2013.
Orexigen Therapeutics, Inc. made up ﹤0.01% of Knight Capital Group's portfolio in Q2 2013, its #2764 holding.
123 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2013.

Based on Knight Capital Group's 13F filing for Q2 2013, filed 8 Aug 2013.